Human Bone Morphogenetic Protein 7 ELISA , BMP7
- Known as:
- Human Bone Morphogenetic Protein 7 Enzyme-linked immunosorbent assay test , BMP7
- Catalog number:
- E01B0390
- Product Quantity:
- 96 Tests/kit
- Category:
- -
- Supplier:
- BGene
- Gene target:
- Human Bone Morphogenetic Protein 7 ELISA BMP7
Related genes to: Human Bone Morphogenetic Protein 7 ELISA , BMP7
- Gene:
- BMP7 NIH gene
- Name:
- bone morphogenetic protein 7
- Previous symbol:
- -
- Synonyms:
- OP-1
- Chromosome:
- 20q13.31
- Locus Type:
- gene with protein product
- Date approved:
- 1991-06-05
- Date modifiied:
- 2016-10-05
Related products to: Human Bone Morphogenetic Protein 7 ELISA , BMP7
Related articles to: Human Bone Morphogenetic Protein 7 ELISA , BMP7
- Two recombinant bone morphogenetic proteins (BMP-2 and BMP-7) have received FDA approval for bone-related therapies. However, their clinical performance is limited by high costs, the need for supraphysiological doses, and adverse side effects. Here, we describe a chemically modified mRNA (cmRNA) encoding BMP-7 that promotes osteogenesis and functional ossification. The BMP-7 cmRNA is delivered using optimized lipid vectors and a composite fibrin-calcium phosphate scaffold. Among several lipids evaluated, two previously unexplored lipids efficiently condense mRNA and mediate its delivery. Transfer of BMP-7 cmRNA lipoplexes to human mesenchymal stromal cells activates intracellular vesicle transport and cytoskeletal remodeling, and regulates extracellular matrix production and calcium-associated processes. These responses were accompanied by robust mineralization and activation of key osteogenic pathways. , BMP-7 mRNA-activated scaffolds promote the formation of ossified tissue, with the highest dose yielding the largest ectopic bony growth. We further observe concurrent angiogenesis and neurogenesis, demonstrating coordinated tissue regeneration. This platform enables effective mRNA delivery for bone healing and can be applied to other tissues, facilitating the development of mRNA therapeutics in regenerative medicine. - Source: PubMed
Publication date: 2026/05/29
Del Toro Runzer ClaudiaRoumans NadiaBouwman Freek GPereira Herrera BetzabethCillero-Pastor BertaRoque MicaelaAmédée JoëlleBovine Elisede Groot Florence BarrèrePlank ChristianBanfi Andreadi Maggio Nunziavan Griensven MartijnBalmayor Elizabeth R - To investigate the therapeutic effects of bone marrow mesenchymal stem cells (BMSCs) preconditioned with low-magnitude high-frequency (LMHF) vibration on temporomandibular joint osteoarthritis (TMJOA). - Source: PubMed
Publication date: 2026/06/08
Hou WeiweiYu MingyueHan JieLi Wen - This study explored low-magnitude high-frequency (LMHF) mechanical vibration as a strategy to expand mandibular condylar chondrocyte (MCC) populations with enhanced chondrogenic phenotypes, providing high-quality cellular resources for cartilage tissue engineering. - Source: PubMed
Publication date: 2026/05/15
Hou WeiweiYu MingyueShen TianjiaoLi Wen - Obstructive uropathy remains a major contributor to pediatric chronic kidney disease. Reliable biomarkers that predict disease progression or recovery are still lacking. Bone morphogenetic protein-7 (BMP-7), known for its anti-fibrotic and renoprotective properties, has been proposed as a promising biomarker in renal injury. This study aimed to assess serum and urinary BMP-7 levels in pediatric obstructive uropathy and to evaluate its potential diagnostic and prognostic significance. - Source: PubMed
Publication date: 2026/05/21
Shirazi MehdiHosseini Seyed HosseinSalehi MaryamShirazi Sania - To map and categorize the existing literature on the use of bone morphogenetic proteins (BMPs) in dentinogenesis and pulp tissue regeneration, identifying research trends, experimental approaches, and knowledge gaps to inform future studies and potential clinical translation. - Source: PubMed
Publication date: 2026/05/18
Portes-Zeno Ana PaulaDos Santos Alexandre GuimarãesSipert Carla RenataFonseca-Gonçalves AndréaRisso Patrícia AndradeMaia Lucianne Cople